MicroRNAs in the pathophysiology of Alzheimer’s disease and Parkinson's disease: an overview

被引:0
|
作者
Mohammad Rafi Khezri
Keyvan Yousefi
Naime Majidi Zolbanin
Morteza Ghasemnejad-Berenji
机构
[1] Urmia University of Medical Sciences,Department of Pharmacology and Toxicology, Faculty of Pharmacy
[2] University of Miami-Miller School of Medicine,Department of Molecular and Cellular Pharmacology
[3] Urmia University of Medical Sciences,Experimental and Applied Pharmaceutical Research Center
[4] Urmia University of Medical Sciences,Department of Pharmacology and Toxicology, School of Pharmacy
来源
Molecular Neurobiology | 2022年 / 59卷
关键词
microRNA; Alzheimer’s disease; Parkinson's disease; Neurodegenerative; CNS;
D O I
暂无
中图分类号
学科分类号
摘要
Neurodegenerative diseases are characterized by a progressive loss of neurons of the central nervous system (CNS) and serve as a major cause of morbidity, mortality and functional dependence especially among the elderly. Despite extensive research and development efforts, the success rate of clinical pipelines has been very limited. However, microRNAs (miRs) have been proved to be of crucial importance in regulating intracellular pathways for various pathologic conditions including those of a neurodegenerative nature. There is ample evidence of altered levels of various miRs in clinical samples of Alzheimer’s disease and Parkinson's disease patients with potentially major clinical implications. In the current review, we aim to summarize the relevant literature on the role of miRs in the pathophysiology of Alzheimer’s disease (AD) and Parkinson's disease (PD) as the two globally predominant neurodegenerative conditions.
引用
收藏
页码:1589 / 1603
页数:14
相关论文
共 50 条
  • [31] Alzheimer's disease: An overview
    Hamdy, RC
    SOUTHERN MEDICAL JOURNAL, 2001, 94 (07) : 661 - 662
  • [32] Tau in the Pathophysiology of Parkinson’s Disease
    Lina Pan
    Lanxia Meng
    Mingyang He
    Zhentao Zhang
    Journal of Molecular Neuroscience, 2021, 71 : 2179 - 2191
  • [33] Physiology and pathophysiology of Parkinson's disease
    Hamani, C
    Lozano, AM
    PARKINSON'S DISEASE: THE LIFE CYCLE OF THE DOPAMINE NEURON, 2003, 991 : 15 - 21
  • [34] Pathophysiology of Parkinson's disease: an update
    Tremblay, Leon
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2010, 194 (07): : 1321 - 1331
  • [35] The Regulation of microRNAs in Alzheimer's Disease
    Kou, Xianjuan
    Chen, Dandan
    Chen, Ning
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [36] Tau in the Pathophysiology of Parkinson's Disease
    Pan, Lina
    Meng, Lanxia
    He, Mingyang
    Zhang, Zhentao
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2021, 71 (11) : 2179 - 2191
  • [37] Pathophysiology of Sporadic Parkinson's Disease
    Braak, H.
    Del Tredici, K.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2010, 78 : S2 - S4
  • [38] Pathophysiology of bradykinesia in Parkinson's disease
    Berardelli, A
    Rothwell, JC
    Thompson, PD
    Hallet, M
    BRAIN, 2001, 124 : 2131 - 2146
  • [39] Approach to the pathophysiology of Alzheimer's disease
    Lucia Jimenez, Martha
    UNIVERSITAS MEDICA, 2005, 46 (01): : 22 - 26
  • [40] The genetics and pathophysiology of Alzheimer's disease
    Lannfelt, L
    JOURNAL OF INTERNAL MEDICINE, 1997, 242 (04) : 281 - 284